Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy in patients with newly diagnosed glioblastoma.

Samuel RyuXiaobu YeJeffrey J OlsonTom MikkelsenLev BangiyevGlenn J LesserTracy BatchelorBurt NaborsSerena DesideriTobias WalbertStuart A Grossman

Published in: Neuro-oncology advances (2024)

ATO with standard radiation is well tolerated in patients with newly diagnosed glioblastoma. Even without temozolomide or adjuvant therapy, the overall survival of all patients (17.7 months) and especially patients who received biweekly ATO (22.8 months) is surprising and accompanied by pharmacodynamic changes on MRI. Further studies of this regimen are warranted.

Keyphrases

newly diagnosed
early stage
magnetic resonance imaging
end stage renal disease
radiation therapy
radiation induced
chronic kidney disease
computed tomography
heavy metals
ejection fraction
case control